Abstract：Objective: To investigate the association and functional role of miR-371a-5p and leucine zipper tumor suppressor 2 (LZTS2) in triple-negative breast cancer (TNBC). Methods: TNBC tissues and adjacent non-tumor tissues were collected from 60 patients who underwent radical surgery at our hospital between October 2021 and October 2023. The relative expression levels of LZTS2 mRNA in TNBC tissues and cells were analyzed by qRT-PCR. CCK-8, scratch healing assay and Transwell were performed to evaluate the cell proliferation, migration and invasion. Expression of LZTS2 and epithelial-mesenchymal transition (EMT)-related proteins were detected by Western blot. The relationship between miR-371a-5p and LZTS2 in TNBC cells was detected by Dual-luciferase reporter assays. Xenograft tumor experiments were performed to examine the impacts of miR-371a-5p on LZTS2 expression and tumor growth in vivo. Results: LZTS2 mRNA expression was decreased in TNBC tissues and cells (t=98.590,F=178.41,P<0.05); overexpression of LZTS2 can inhibit invasion, migration, proliferation, and EMT of TNBC cells (P<0.05); LZTS2 was a target gene of miR-371a-5p (t=26.778, P<0.05); In addition, overexpression of LZTS2 weakened the promotion effect of overexpression of miR-371a-5p on TNBC cells proliferation, migration, invasion and EMT (P<0.05). In vivo experiments confirmed that miR-371a-5p regulated LZTS2 mRNA to inhibit tumor growth (P<0.05). Conclusion: miR-371a-5p may accelerate TNBC cell proliferation, migration, invasion, and EMT by targeting LZTS2, providing a new potential therapeutic target for TNBC.
[1] Jafari SH,Jahanmir A,Bahramvand Y,et al.Association of estrogen receptor,progesterone receptor,and human epidermal growth factor receptor 2 expression with breast cancer metastasis in iran[J].Iran Med Sci,2022,47(1):40-47. [2] Asano Y,Kashiwagi S,Takada K,et al.Clinical significance of expression of immunoadjuvant molecules (LAG-3,TIM-3,OX-40) in neoadjuvant chemotherapy for breast cancer[J].Anticancer Res,2022,42(1):125-136. [3] Lu Y,Li X,Liu H,et al.β-Trcp and CK1δ-mediated degradation of LZTS2 activates PI3K/AKT signaling to drive tumorigenesis and metastasis in hepatocellular carcinoma[J].Oncogene,2021,40(7):1269-1283. [4] Zhang J,Zhang L,Wang J,et al.Long non-coding RNA linc00921 suppresses tumorigenesis and epithelial-to-mesenchymal transition of triple-negative breast cancer via targeting miR-9-5p/LZTS2 axis[J].Hum Cell,2022,18(4):1-12. [5] Yue L,Guo J.LncRNA TUSC7 suppresses pancreatic carcinoma progression by modulating miR-371a-5p expression[J].Cell Physiol,2019,4(1):1-11. [6] Wang C,Feng G,Zhu J,et al.Developing an immune signature for triple-negative breast cancer to predict prognosis and immune checkpoint inhibitor response[J].Future Oncol,2022,18(9):1055-1066. [7] Lipsick J.A history of cancer research: tumor suppressor genes[J].Cold Spring Harb Perspect Biol,2020,12(2):35907-35918. [8] Kim DS,Camacho CV,Setlem R,et al.Functional characterization of lncRNA152 as an angiogenesis-inhibiting tumor suppressor in triple-negative breast cancers[J].Mol Cancer Res,2022,20(11):1623-1635. [9] Shen Z,Lin L,Cao B,et al.LZTS2 promoter hypermethylation: a potential biomarker for the diagnosis and prognosis of laryngeal squamous cell carcinoma[J].World Surg Oncol,2018,16(1):42-48. [10] Kaleem M,Perwaiz M,Nur SM,et al.Epigenetics of triple-negative breast cancer via natural compounds[J].Curr Med Chem,2022,29(8):1436-1458. [11] Kerche LE,de Sousa EA,Squarize CH,et al.EMT in salivary gland tumors: the expression of microRNAs miR-155 and miR-200c is associated with clinical-pathological parameters[J].Mol Biol Rep,2022,49(3):2157-2167. [12] Brlek P,Bukovac A,Kafka A,et al.TWIST1 upregulation affects E-cadherin expression in brain metastases[J].Clin Transl Oncol,2021,23(6):1085-1095. [13] Jang HY,Lim SM,Lee HJ,et al.Identification of microRNAs and their target genes in the placenta as biomarkers of inflammation[J].Clin Exp Reprod Med,2020,47(1):42-53. [14] Gungormez C,Teker E,Atmanoglu S,et al.miRNA profile and bioinformatic analysis for diagnosis in patients with stage ⅢA colon cancer[J].Biochem Genet,2022,60(1):191-203.
2025, Vol. 31 
冀公网安备13080202000786号